Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Trial of FOLFOXIRI + bevacizumab vs FOLFIRI + bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer
2008-001537-10Phase 3Completed
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Jan 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of bevacizumab in metastatic colon cancer (mCRC) and gastrointestinal cancer (2 arms), sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoint: progression-free survival. Started Jan 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
metastatic colon cancer (mCRC)gastrointestinal cancer
Beyond the preview
Go deeper on 2008-001537-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001537-10.